Study of Gene Modified Immune Cells in Patients With Advanced Melanoma

NCT00910650 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

14

Enrollment

OTHER

Sponsor class

Conditions

Metastatic Melanoma

Interventions

BIOLOGICAL: F5 TCR transgenic cells and MART-1 peptide pulsed dendritic cells
DRUG: non-myeloablative conditioning chemotherapy

Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]